Log In
Print this Print this

Teneligliptin/Canagliflozin (MT-2412)

  Manage Alerts
Collapse Summary General Information
Company Mitsubishi Tanabe Pharma Corp.
DescriptionOral fixed dose combination of Teneligliptin and Canagliflozin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26) ; Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor; Dipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat type 2 diabetes mellitus
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today